22.46
-1.98(-8.10%)
Currency In USD
| Previous Close | 24.44 |
| Open | 24.58 |
| Day High | 24.58 |
| Day Low | 21.38 |
| 52-Week High | 32.44 |
| 52-Week Low | 20.16 |
| Volume | 122,941 |
| Average Volume | 156,397 |
| Market Cap | 750.76M |
| PE | -17.97 |
| EPS | -1.25 |
| Moving Average 50 Days | 26.73 |
| Moving Average 200 Days | 26.73 |
| Change | -1.98 |
Data not available
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
GlobeNewswire Inc.
Mar 09, 2026 12:00 PM GMT
97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vision, demonstrating high quality of vision, perform
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit
GlobeNewswire Inc.
Mar 04, 2026 1:00 PM GMT
ALISO VIEJO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced that members of the executive management team will host 1x1 meetings at the Jef
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Feb 09, 2026 9:05 PM GMT
ALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the closing of its initial public offering of 10,781,250 shares of its common st